Search research articles
Contact Us
Filters
Showing results (161-170 of 271) with videos related to
Page
of 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Urologic Oncology
|
September 23, 2021
Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival
Alberto C Pieretti, Daniel D Shapiro, Mary E Westerman, et al.
Urologic Oncology
|
December 29, 2015
Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy
Leonardo D Borregales, Dae Y Kim, Angie L Staller, et al.
The Oncologist
|
April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
Andrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
European Urology Focus
|
September 22, 2024
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma
Emily Wang, Eric S Rupe, Sagar S Mukhida, et al.
Clinical Genitourinary Cancer
|
June 15, 2019
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
Giuseppe Procopio, Aristotelis Bamias, Manuela Schmidinger, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
May 6, 2005
Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes
Kamran Ahrar, Surena Matin, Christopher G Wood, et al.
Urologic Oncology
|
July 24, 2021
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma
Alberto C Pieretti, Mary E Westerman, Alexandria Childs, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
JCO Oncology Practice
|
September 21, 2020
Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
Cristiane Decat Bergerot, Dena Battle, Errol J Philip, et al.
Page
of 28
Search research articles
Search
Showing results (161-170 of 271) with videos related to
Sort By:
Page
of 28
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Urologic Oncology
|
September 23, 2021
Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival
Alberto C Pieretti, Daniel D Shapiro, Mary E Westerman, et al.
Urologic Oncology
|
December 29, 2015
Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy
Leonardo D Borregales, Dae Y Kim, Angie L Staller, et al.
The Oncologist
|
April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC
Andrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
European Urology Focus
|
September 22, 2024
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma
Emily Wang, Eric S Rupe, Sagar S Mukhida, et al.
Clinical Genitourinary Cancer
|
June 15, 2019
Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
Giuseppe Procopio, Aristotelis Bamias, Manuela Schmidinger, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
May 6, 2005
Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes
Kamran Ahrar, Surena Matin, Christopher G Wood, et al.
Urologic Oncology
|
July 24, 2021
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma
Alberto C Pieretti, Mary E Westerman, Alexandria Childs, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
JCO Oncology Practice
|
September 21, 2020
Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
Cristiane Decat Bergerot, Dena Battle, Errol J Philip, et al.
Page
of 28